Market performance of featured public companies, Oct 26th-30th.
Field Trip Health ($FTRP | $FTRPF) provided an update on its lead drug candidate, FT-104. Results confirmed that their novel psychedelic molecule is similar in potency to psilocybin but with shorter duration of psychoactivity. Press Release
ATAI Life Sciences (Private) announced that Neuronasal Inc has completed its pilot study and has been granted Investigational New Drug clearance by the FDA to continue phase I clinical trial development of their mTBI therapeutic. Press Release
MagicMed Industries (Private) announced an agreement with the University of Calgary to accelerate development of the Psybrary™, MagicMed’s psychedelic derivates patent library. Press Release
Psyched Wellness ($PSYC) added Brian Tancowny to their Scientific Advisory Board, joining Professor David Nutt, as the company progresses through pre-clinical trials for Amanita Muscaria. Press Release
MindMed ($MMED | $MMEDF) closed their upsized bought deal financing for gross proceeds of C$28,750,575. MindMed now has cash reserves of C$50.1M. Press Release
Pharmather ($PHRM) filed an application with the FDA to receive Orphan Drug Designation for ketamine in the treatment of neuropathic pain. Press Release
Havn Life Sciences ($HAVN) is supporting the first modern psilocybin depression study in Germany with MIND Foundation. Press Release